Literature DB >> 22402863

Spectrum of cognitive impairment in neurocysticercosis: differences according to disease phase.

C L Rodrigues1, D C de Andrade, J A Livramento, L R Machado, R Abraham, L Massaroppe, L T Lucato, P Caramelli.   

Abstract

OBJECTIVES: Cognitive decline related to neurocysticercosis (NC) remains poorly characterized and underdiagnosed. In a cross-sectional study with a prospective phase, we evaluated cognitive decline in patients with strictly calcified form (C-NC), the epidemiologically largest subgroup of NC, and investigated whether there is a spectrum of cognitive abnormalities in the disease.
METHODS: Forty treatment-naive patients with C-NC aged 37.6 ± 11.3 years and fulfilling criteria for definitive C-NC were submitted to a comprehensive cognitive and functional evaluation and were compared with 40 patients with active NC (A-NC) and 40 healthy controls (HC) matched for age and education. Patients with dementia were reassessed after 24 months.
RESULTS: Patients with C-NC presented 9.4 ± 3.1 altered test scores out of the 30 from the cognitive battery when compared to HC. No patient with C-NC had dementia and 10 patients (25%) presented cognitive impairment-no dementia (CIND). The A-NC group had 5 patients (12.5%) with dementia and 11 patients (27.5%) with CIND. On follow-up, 3 out of 5 patients with A-NC with dementia previously still presented cystic lesions with scolex on MRI and still had dementia. One patient died and the remaining patient no longer fulfilled criteria for either dementia or CIND, presenting exclusively calcified lesions on neuroimaging.
CONCLUSIONS: Independently of its phase, NC leads to a spectrum of cognitive abnormalities, ranging from impairment in a single domain, to CIND and, occasionally, to dementia. These findings are more conspicuous during active vesicular phase and less prominent in calcified stages.

Entities:  

Mesh:

Year:  2012        PMID: 22402863     DOI: 10.1212/WNL.0b013e31824c46d1

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  13 in total

Review 1.  Clinical symptoms, diagnosis, and treatment of neurocysticercosis.

Authors:  Hector H Garcia; Theodore E Nash; Oscar H Del Brutto
Journal:  Lancet Neurol       Date:  2014-11-10       Impact factor: 44.182

Review 2.  Omental transplantation for neurodegenerative diseases.

Authors:  Hernando Rafael
Journal:  Am J Neurodegener Dis       Date:  2014-09-06

3.  The Association between Calcified Neurocysticercosis and Cognitive Performance: A Case-Control Study Nested to a Population-Based Cohort.

Authors:  Oscar H Del Brutto; Robertino M Mera; Mauricio Zambrano; Aldo F Costa; Gustavo C Román
Journal:  Am J Trop Med Hyg       Date:  2019-02       Impact factor: 2.345

4.  An Unusual Presentation of Neurocysticercosis: A Space-Occupying Lesion in the Fourth Ventricle Associated with Progressive Cognitive Decline.

Authors:  Carolin Kurz; Veronika Schmidt; Holger Poppert; Patricia Wilkins; John Noh; Sven Poppert; Jürgen Schlegel; Claire Delbridge; Clarissa Prazeres da Costa; Andrea S Winkler
Journal:  Am J Trop Med Hyg       Date:  2015-11-30       Impact factor: 2.345

5.  Quantification of Amino Acid Neurotransmitters in Cerebrospinal Fluid of Patients with Neurocysticercosis.

Authors:  José Augusto Camargo; Paulo Henrique Ferreira Bertolucci
Journal:  Open Neurol J       Date:  2015-06-10

6.  Racemose neurocysticercosis and reversible dementia.

Authors:  Somsri Wiwanitkit; Viroj Wiwanitkit
Journal:  Ann Indian Acad Neurol       Date:  2013-10       Impact factor: 1.383

7.  Prevalence and risk factors for Taenia solium cysticercosis in school-aged children: A school based study in western Sichuan, People's Republic of China.

Authors:  John J Openshaw; Alexis Medina; Stephen A Felt; Tiaoying Li; Zhou Huan; Scott Rozelle; Stephen P Luby
Journal:  PLoS Negl Trop Dis       Date:  2018-05-08

8.  Neurocysticercosis Among Zambian Children and Adolescents With Human Immunodeficiency Virus: A Geographic Information Systems Approach.

Authors:  Alexandra Buda; Owen Dean; Heather R Adams; Sylvia Mwanza-Kabaghe; Michael J Potchen; Esau G Mbewe; Pelekelo P Kabundula; Sarah Mohajeri Moghaddam; Milimo Mweemba; Beauty Matoka; Manoj M Mathews; Gretchen L Birbeck; David R Bearden
Journal:  Pediatr Neurol       Date:  2019-08-06       Impact factor: 3.372

9.  Cognitive and surgical outcome in mesial temporal lobe epilepsy associated with hippocampal sclerosis plus neurocysticercosis: a cohort study.

Authors:  Marino M Bianchin; Tonicarlo R Velasco; Erica R Coimbra; Ana C Gargaro; Sara R Escorsi-Rosset; Lauro Wichert-Ana; Vera C Terra; Veriano Alexandre; David Araujo; Antonio Carlos dos Santos; Regina M F Fernandes; João A Assirati; Carlos G Carlotti; João P Leite; Osvaldo M Takayanagui; Hans J Markowitsch; Américo C Sakamoto
Journal:  PLoS One       Date:  2013-04-22       Impact factor: 3.240

10.  Reversible dementia due to neurocysticercosis: Improvement of the racemose type with antihistamines.

Authors:  Gislaine Cristina Lopes Machado-Porto; Leandro Tavares Lucato; Fábio Henrique de Gobbi Porto; Evandro Cesar de Souza; Ricardo Nitrini
Journal:  Dement Neuropsychol       Date:  2015 Jan-Mar
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.